港股异动 | 轩竹生物-B(02575)早盘涨超18% 吡洛西利III期BRIGHT-2临床研究结果于国际医学顶刊发表

智通财经03-26

智通财经APP获悉，轩竹生物-B(02575)早盘涨超18%，截至发稿，涨11.85%，报40.58港元，成交额1886.4万港元。消息面上，3月24日，轩竹生物-B发布公告，公司自主研发的新型CDK2/4/6抑制剂吡洛西利(Bireociclib)的III期BRIGHT-2临床研究最终分析结果，已于近日在国际顶尖医学期刊《美国医学会杂志·肿瘤学》(JAMA Oncology，医学1区，影响因子...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2622881272?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-03-26 09:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2622881272","market":"sh","top_or_hot":-1,"title":"港股异动 | 轩竹生物-B(02575)早盘涨超18% 吡洛西利III期BRIGHT-2临床研究结果于国际医学顶刊发表","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，轩竹生物-B(02575)早盘涨超18%，截至发稿，涨11.85%，报40.58港元，成交额1886.4万港元。消息面上，3月24日，轩竹生物-B发布公告，公司自主研发的新型CDK2/4/6抑制剂吡洛西利(Bireociclib)的III期BRIGHT-2临床研究最终分析结果，已于近日在国际顶尖医学期刊《美国医学会杂志·肿瘤学》(JAMA Oncology，医学1区，影响因子...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1419250.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>港股异动 | 轩竹生物-B(02575)早盘涨超18% 吡洛西利III期BRIGHT-2临床研究结果于国际医学顶刊发表</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n港股异动 | 轩竹生物-B(02575)早盘涨超18% 吡洛西利III期BRIGHT-2临床研究结果于国际医学顶刊发表\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-26 09:47 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1419250.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，轩竹生物-B(02575)早盘涨超18%，截至发稿，涨11.85%，报40.58港元，成交额1886.4万港元。消息面上，3月24日，轩竹生物-B发布公告，公司自主研发的新型CDK2/4/6抑制剂吡洛西利(Bireociclib)的III期BRIGHT-2临床研究最终分析结果，已于近日在国际顶尖医学期刊《美国医学会杂志·肿瘤学》(JAMA Oncology，医学1区，影响因子...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1419250.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4134","symbol_name":"信息科技咨询与其它服务","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1419250.html","article_id":"2622881272","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2622881272","pubTimestamp":1774489669,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，轩竹生物-B早盘涨超18%，截至发稿，涨11.85%，报40.58港元，成交额1886.4万港元。消息面上，3月24日，轩竹生物-B发布公告，公司自主研发的新型CDK2/4/6抑制剂吡洛西利的III期BRIGHT-2临床研究最终分析结果，已于近日在国际顶尖医学期刊《美国医学会杂志·肿瘤学》正式在线全文发表。公司曾于2025年4月在《Nature Communications》期刊上公布BRIGHT-2研究的中期分析结果。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4134":"信息科技咨询与其它服务","000516":"国际医学","BK0146":"智慧医疗","BK0046":"生物疫苗","BK0181":"保底增持","III":"信息服务","BK4588":"碎股","BK0236":"卫生","BK0096":"民营医院","BK1191":"制药","BK0188":"融资融券","BK0114":"健康中国","BK4585":"ETF&股票定投概念","02575":"轩竹生物-B","VXUS":"国际股票ETF-Vanguard","BK0077":"质押式回购","BK0042":"基因检测"},"translate_title":"Changes in Hong Kong stocks | Xuanzhu Bio-B (02575) rose by more than 18% in early trading The results of the Phase III BRIGHT-2 clinical study of piroxilide were published in the top international medical journal","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02575":1.5,"III":1.5,"000516":1.5,"VXUS":1.5},"content_text":"智通财经APP获悉，轩竹生物-B(02575)早盘涨超18%，截至发稿，涨11.85%，报40.58港元，成交额1886.4万港元。消息面上，3月24日，轩竹生物-B发布公告，公司自主研发的新型CDK2/4/6抑制剂吡洛西利(Bireociclib)的III期BRIGHT-2临床研究最终分析结果，已于近日在国际顶尖医学期刊《美国医学会杂志·肿瘤学》(JAMA Oncology，医学1区，影响因子20.1)正式在线全文发表。BRIGHT-2研究是一项在中国开展的随机、双盲、安慰剂对照、多中心III期临床试验，旨在评估吡洛西利联合氟维司群在既往内分泌治疗进展后的激素受体阳性(HR+)、人类表皮生长因子受体2阴 性(HER2-)(HR+/HER2-)晚期乳腺癌患者中的疗效与安全性。本研究由中国医学科学院肿瘤医院徐兵河院士牵头，在全国64家医院开展。公司曾于2025年4月在《Nature Communications》期刊上公布BRIGHT-2研究的中期分析结果。本次发表的为最终分析结果，在中期分析的基础上增加额外11个月的观察期，中位随访时间已延长至19个月，进一步揭示了吡洛西利在生存获益上的成熟度与稳健性。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2622881272","isCrawlerRequest":true}